AI Engines For more Details: Perplexity Kagi Labs You
Antipsychotic Effect: Benperidol belongs to the class of medications known as typical antipsychotics. It exerts its therapeutic effects by blocking dopamine receptors in the brain, particularly dopamine D2 receptors. By inhibiting dopamine neurotransmission, benperidol helps alleviate symptoms of psychosis such as hallucinations, delusions, disorganized thinking, and agitation.
Treatment of Schizophrenia: Schizophrenia is a chronic mental disorder characterized by disturbances in perception, thought processes, emotions, and behavior. Benperidol is used as a part of the comprehensive treatment regimen for schizophrenia to control symptoms and improve patients' overall functioning and quality of life.
Management of Other Psychotic Disorders: In addition to schizophrenia, benperidol may also be prescribed for other psychotic disorders, such as schizoaffective disorder, psychotic depression, and psychotic symptoms associated with bipolar disorder or organic brain syndromes.
Control of Agitation and Aggression: Benperidol may be effective in reducing agitation, aggression, and hostility in patients with psychotic disorders. By modulating dopamine activity in certain brain regions, it helps stabilize mood and behavior.
Maintenance Therapy: In some cases, benperidol may be used for long-term maintenance therapy to prevent the recurrence of psychotic symptoms and maintain symptom control in patients with chronic psychotic disorders.
Off-label Uses: In addition to its approved indications, benperidol may be prescribed off-label for other conditions such as severe anxiety, severe agitation, and certain movement disorders. However, the use of benperidol for these purposes should be carefully monitored and managed by a qualified healthcare professional.
Side Effects: Like other antipsychotic medications, benperidol can cause a range of side effects, including extrapyramidal symptoms (such as tremors, rigidity, and involuntary muscle movements), sedation, dizziness, orthostatic hypotension (low blood pressure upon standing), weight gain, and metabolic changes (such as increased blood sugar and lipid levels).
Cardiovascular Effects: Benperidol may prolong the QT interval on the electrocardiogram (ECG), which can increase the risk of cardiac arrhythmias, including torsades de pointes and sudden cardiac death. Therefore, caution is advised when prescribing benperidol, especially in patients with preexisting cardiovascular conditions or those taking other medications that can prolong the QT interval.
Neurological Effects: In rare cases, benperidol may be associated with the development of neuroleptic malignant syndrome (NMS), a potentially life-threatening condition characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. Prompt recognition and management of NMS are essential to prevent complications.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.4 | 0 | 0 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0 | 0 |
| Allergic Rhinitis (Hay Fever) | 0 | 0 | |
| Allergies | 0.3 | -0.3 | |
| Allergy to milk products | 0 | 0 | |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0 | 0.9 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | |
| Ankylosing spondylitis | 0.5 | 0.5 | |
| Anorexia Nervosa | 0 | 0.3 | 0 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0.1 | -0.1 | |
| Atherosclerosis | 0.2 | -0.2 | |
| Atrial fibrillation | 0.4 | 0.3 | 0.33 |
| Autism | 0.5 | 1.1 | -1.2 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0 | 0.1 | 0 |
| Brain Trauma | 0.1 | -0.1 | |
| Cancer (General) | 0.1 | -0.1 | |
| Carcinoma | 0.1 | 0 | 0 |
| Celiac Disease | 0.1 | 0 | 0 |
| Cerebral Palsy | 0.1 | 0.1 | 0 |
| Chronic Fatigue Syndrome | 0.2 | 0.9 | -3.5 |
| Chronic Kidney Disease | 0 | 0.7 | 0 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.1 | 1 |
| Chronic Urticaria (Hives) | 0.1 | 0.3 | -2 |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.1 | 0 |
| Colorectal Cancer | 0.3 | 0.3 | 0 |
| Constipation | 0.1 | -0.1 | |
| Coronary artery disease | 0.3 | 0 | 0 |
| COVID-19 | 0.2 | 1.6 | -7 |
| Crohn's Disease | 0.1 | 0.7 | -6 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0.1 | -0.1 | |
| Depression | 0.7 | 1.2 | -0.71 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.2 | -0.2 | |
| Endometriosis | 0.2 | 0.2 | |
| Epilepsy | 0.1 | 0.1 | 0 |
| Fibromyalgia | 0.1 | 0.4 | -3 |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.4 | -1 |
| gallstone disease (gsd) | 0 | 0.1 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
| Generalized anxiety disorder | 0 | 0 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0 | 0 | |
| Graves' disease | 0 | 0.1 | 0 |
| Halitosis | 0.1 | -0.1 | |
| Hashimoto's thyroiditis | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| High Histamine/low DAO | 0.1 | 0.1 | |
| hyperglycemia | 0 | 0 | |
| hypertension (High Blood Pressure | 0.1 | 0.2 | -1 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 0 | 0 | |
| IgA nephropathy (IgAN) | 0.3 | -0.3 | |
| Inflammatory Bowel Disease | 0.2 | 1.5 | -6.5 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intelligence | 0 | 0.3 | 0 |
| Intracranial aneurysms | 0 | 0 | |
| Irritable Bowel Syndrome | 0.1 | 0.1 | 0 |
| Liver Cirrhosis | 0.2 | 0.2 | 0 |
| Long COVID | 0.5 | 0.4 | 0.25 |
| Low bone mineral density | 0.1 | -0.1 | |
| Mast Cell Issues / mastitis | 0.1 | 0 | 0 |
| ME/CFS with IBS | 0.1 | 0.1 | 0 |
| ME/CFS without IBS | 0.2 | 0.1 | 1 |
| Metabolic Syndrome | 0.2 | 0.2 | 0 |
| Mood Disorders | 0.8 | 1.2 | -0.5 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
| Multiple Sclerosis | 0.3 | 1.2 | -3 |
| Neuropathy (all types) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.6 | -0.5 |
| Obesity | 0.2 | 0.3 | -0.5 |
| obsessive-compulsive disorder | 0.1 | 0.6 | -5 |
| Osteoarthritis | 0.1 | 0.1 | |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.5 | 0.9 | -0.8 |
| Polycystic ovary syndrome | 0 | 0.1 | 0 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Premenstrual dysphoric disorder | 0 | 0 | |
| Psoriasis | 0.1 | 0.6 | -5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.5 | 0.1 | 4 |
| Rosacea | 0.1 | -0.1 | |
| Schizophrenia | 0.1 | 0.1 | 0 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 0.4 | 0.3 | 0.33 |
| Sleep Apnea | 0 | 0.1 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.1 | 0.1 | 0 |
| Systemic Lupus Erythematosus | 0.2 | 0.1 | 1 |
| Tic Disorder | 0.3 | -0.3 | |
| Type 1 Diabetes | 0 | 0.1 | 0 |
| Type 2 Diabetes | 0.2 | 0.2 | 0 |
| Ulcerative colitis | 0.1 | 0.4 | -3 |
| Unhealthy Ageing | 0.1 | 0.7 | -6 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription
All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [44.222.131 ]
Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.131 ]
